Welcome to Idorsia

Looking for more information
on lupus?

When should we be celebrating our birthday?

Read about how Idorsia was born…

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s future success entirely depends on our people.

Idorsia's development compounds target a number of different diseases.

07 Jan 2019	Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus
18 Dec 2018	Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective
20 Nov 2018	Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone

Event	When
Full-Year 2018 Financial Results reporting*	February 7, 2019
First Quarter 2019 Financial Results reporting*	April 18, 2019
Annual General Meeting 2019	May 3, 2019
Half-Year 2019 Financial Results reporting*	July 23, 2019

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:30:51 CET

17.19 CHF

-0.07 (-0.41 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland